Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AZD3293

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

- PMLiVE

AZ drug for opioid constipation starts FDA review

Naloxegol on course to compete with Takeda’s Amitiza

- PMLiVE

MedImmune appoints head of research

Yong-Jun Liu to lead R&D at AstraZeneca biologics subsidiary

- PMLiVE

AZ invests £120m in UK cancer drug production

New facility in Macclesfield to manufacture Zoladex will retain 300 jobs

- PMLiVE

AZ strikes antibiotic deal with Singapore research unit

Deal with A*STAR to tackle antimicrobial resistance

- PMLiVE

AZ names Dunoyer as CFO

He succeeds Simon Lowth as company restructure continues apace

- PMLiVE

AZ takes severe asthma antibody into phase III

Benralizumab shows promise in clinical trials

- PMLiVE

FDA approves Alzheimer’s diagnostic drug

GE Healthcare's Vizamyl to compete with Lilly's Amyvid

- PMLiVE

AstraZeneca to close UK environmental lab

Decision on Brixham facility in Devon puts 71 positions at risk

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

AZ buys into ADC sector with $440m Spirogen deal

Pushes into the market for antibody-drug conjugates

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links